Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner

Park,Ga Bin; Ko,Hyun‑Suk; Kim,Daejin

doi:10.3892/mmr.2017.6773

Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner

Authors:
- Ga Bin Park
- Hyun‑Suk Ko
- Daejin Kim
View Affiliations

Affiliations: Department of Biochemistry, Kosin University College of Medicine, Busan 49267, Republic of Korea, Department of Anatomy, Inje University College of Medicine, Busan 47392, Republic of Korea
Published online on: June 14, 2017 https://doi.org/10.3892/mmr.2017.6773
Pages: 1826-1836
Copyright: © Park et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cluster of differentiation (CD) 44 and epidermal growth factor (EGF) are closely involved in cellular migration and have been used as stem cell markers. Although the hyaluronan (HA)‑binding CD44 is responsible for enhanced cellular motility, the mechanism underlying its actions in various cell types and clinical conditions have yet to be elucidated. In the present study, the multikinase inhibitor sorafenib was used to investigate the diverse effects of EGF stimulation on epithelial‑mesenchymal transition (EMT) in ovarian cancer cells using immunoblotting and reverse transcription‑polymerase chain reaction. In addition, the association between EGF and CD44/HA signaling pathways in the control of mesenchymal phenotype was determined by gene silencing with small interfering RNA transfection. EGF stimulation of ovarian cancer cells increased cellular migration, mesenchymal transition, CD44 expression and the activation of matrix metalloproteinase (MMP)‑2 and MMP‑9. Sorafenib effectively suppressed the loss of epithelial characteristics in EGF‑treated SK‑OV‑3 ovarian cancer cells, via targeting the mitogen‑activated protein kinase (MAPK)/extracellular signal‑regulated kinase (ERK) pathway. Although treatment of Caov‑3 ovarian cancer cells with sorafenib blocked the expression of mesenchymal phenotypes following EGF stimulation, EGF‑activated Caov‑3 cells exhibited reduced MAPK/ERK signaling. Furthermore, EGF‑activated Caov‑3 cells increased the expression of hyaluronan synthase 2 and HA‑CD44 ligation in EGF‑exposed Caov‑3 cells, which resulted in the activation of the Ras/Raf/MEK signaling pathway, amplification of migratory activity and the expression of mesenchymal markers, including N‑cadherin and vimentin. Furthermore, silencing EGFR in SK‑OV‑3 cells and CD44 in Caov‑3 cells suppressed their migratory activity, through inhibition of the MAPK/ERK pathway. The present results suggested that EGF‑mediated signaling may regulate metastasis and invasion of ovarian cancer cells, in a cancer cell type‑dependent manner.

View Figures

View References

1	Heppner G, Yamashina K, Miller B and Miller F: Tumor heterogeneity in metastasis. Prog Clin Biol Res. 212:45–59. 1986.PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Gadducci A, Sartori E, Maggino T, Zola P, Landoni F, Fanucchi A, Palai N, Alessi C, Ferrero AM, Cosio S and Cristofani R: Analysis of failures after negative second-look in patients with advanced ovarian cancer: An Italian multicenter study. Gynecol Oncol. 68:150–155. 1998. View Article : Google Scholar : PubMed/NCBI
4	Bagnato A and Rosanò L: Epithelial-mesenchymal transition in ovarian cancer progression: A crucial role for the endothelin axis. Cells Tissues Organs. 185:85–94. 2007. View Article : Google Scholar : PubMed/NCBI
5	Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
6	Auersperg N, Wong AS, Choi KC, Kang SK and Leung PC: Ovarian surface epithelium: Biology, endocrinology and pathology. Endocr Rev. 22:255–288. 2001. View Article : Google Scholar : PubMed/NCBI
7	Lafky JM, Wilken JA, Baron AT and Maihle NJ: Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 1785:232–265. 2008.PubMed/NCBI
8	Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN and Butzow R: Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl). 84:671–681. 2006. View Article : Google Scholar : PubMed/NCBI
9	Nagano O and Saya H: Mechanism and biological significance of CD44 cleavage. Cancer Sci. 95:930–935. 2004. View Article : Google Scholar : PubMed/NCBI
10	Kim Y, Lee YS, Choe J, Lee H, Kim YM and Jeoung D: CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase and MMP-2. J Biol Chem. 283:22513–22528. 2008. View Article : Google Scholar : PubMed/NCBI
11	Murai T, Miyauchi T, Yanagida T and Sako Y: Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10. Biochem J. 39:65–71. 2006. View Article : Google Scholar
12	Ellis IR, Schor AM and Schor SL: EGF AND TGF-alpha motogenic activities are mediated by the EGF receptor via distinct matrix-dependent mechanisms. Exp Cell Res. 313:732–741. 2007. View Article : Google Scholar : PubMed/NCBI
13	Grass GD, Tolliver LB, Bratoeva M and Toole BP: CD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness. J Biol Chem. 288:26089–26104. 2013. View Article : Google Scholar : PubMed/NCBI
14	Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB and Uppaluri R: ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 72:365–374. 2012. View Article : Google Scholar : PubMed/NCBI
15	Frémin C and Meloche S: From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol. 3:82010. View Article : Google Scholar : PubMed/NCBI
16	Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
17	Zhang J, Chen YL, Ji G, Fang W, Gao Z, Liu Y, Wang J, Ding X and Gao F: Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells. PLoS One. 8:e649542013. View Article : Google Scholar : PubMed/NCBI
18	Yu D, Wolf JK, Scanlon M, Price JE and Hung MC: Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 53:891–898. 1993.PubMed/NCBI
19	Buick RN, Pullano R and Trent JM: Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 45:3668–3676. 1985.PubMed/NCBI
20	Yan L, Zucker S and Toole BP: Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost. 93:199–204. 2005.PubMed/NCBI
21	Marieb EA, Zoltan-Jones A, Li R, Misra S, Ghatak S, Cao J, Zucker S and Toole BP: Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res. 64:1229–1232. 2004. View Article : Google Scholar : PubMed/NCBI
22	Toole BP and Slomiany MG: Hyaluronan, CD44 and Emmprin: Partners in cancer cell chemoresistance. Drug Resist Updat. 11:110–121. 2008. View Article : Google Scholar : PubMed/NCBI
23	La Fleur L, Johansson AC and Roberg K: A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment. PLoS One. 7:e440712012. View Article : Google Scholar : PubMed/NCBI
24	Grandis JR and Sok JC: Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 102:37–46. 2004. View Article : Google Scholar : PubMed/NCBI
25	Kim HR, Wheeler MA, Wilson CM, Iida J, Eng D, Simpson MA, McCarthy JB and Bullard KM: Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer Res. 64:4569–4576. 2004. View Article : Google Scholar : PubMed/NCBI
26	Cook AC, Chambers AF, Turley EA and Tuck AB: Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem. 281:24381–24389. 2006. View Article : Google Scholar : PubMed/NCBI
27	Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, Huang JF, Neudecker BA, Wang FS, Turley EA and Naor D: RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: A different interpretation of redundancy. Proc Natl Acad Sci USA. 101:18081–18086. 2004. View Article : Google Scholar : PubMed/NCBI
28	Kim MS, Park MJ, Kim SJ, Lee CH, Yoo H, Shin SH, Song ES and Lee SH: Emodin suppresses hyaluronic acid-induced MMP-9 secretion and invasion of glioma cells. Int J Oncol. 27:839–846. 2005.PubMed/NCBI
29	Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S and Birembaut P: Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem. 47:1575–1580. 1999. View Article : Google Scholar : PubMed/NCBI
30	Weidle UH, Scheuer W, Eggle D, Klostermann S and Stockinger H: Cancer-related issues of CD147. Cancer Genomics Proteomics. 7:157–169. 2010.PubMed/NCBI
31	Toole BP: Hyaluronan-CD44 interactions in cancer: Paradoxes and possibilities. Clin Cancer Res. 15:7462–7468. 2009. View Article : Google Scholar : PubMed/NCBI
32	Jacobson A, Rahmanian M, Rubin K and Heldin P: Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer. 102:212–219. 2002. View Article : Google Scholar : PubMed/NCBI
33	Chen H, Zhu G, Li Y, Padia RN, Dong Z, Pan ZK, Liu K and Huang S: Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res. 69:9228–9235. 2009. View Article : Google Scholar : PubMed/NCBI
34	Boregowda RK, Appaiah HN, Siddaiah M, Kumarswamy SB, Sunila S, Thimmaiah KN, Mortha K, Toole B and Banerjee Sd: Expression of hyaluronan in human tumor progression. J Carcinog. 5:22006. View Article : Google Scholar : PubMed/NCBI
35	Li Y and Heldin P: Hyaluronan production increases the malignant properties of mesothelioma cells. Br J Cancer. 85:600–607. 2001. View Article : Google Scholar : PubMed/NCBI
36	Tamada Y, Takeuchi H, Suzuki N, Aoki D and Irimura T: Cell surface expression of hyaluronan on human ovarian cancer cells inversely correlates with their adhesion to peritoneal mesothelial cells. Tumour Biol. 33:1215–1222. 2012. View Article : Google Scholar : PubMed/NCBI
37	Ricciardelli C, Ween MP, Lokman NA, Tan IA, Pyragius CE and Oehler MK: Chemotherapy-induced hyaluronan production: A novel chemoresistance mechanism in ovarian cancer. BMC Cancer. 13:4762013. View Article : Google Scholar : PubMed/NCBI
38	Fitzgerald KA, Bowie AG, Skeffington BS and O'Neill LA: Ras, protein kinase C zeta, and I kappa B kinases 1 and 2 are downstream effectors of CD44 during the activation of NF-kappa B by hyaluronic acid fragments in T-24 carcinoma cells. J Immunol. 164:2053–2063. 2000. View Article : Google Scholar : PubMed/NCBI
39	Dudgeon C, Peng R, Wang P, Sebastiani A, Yu J and Zhang L: Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth. Oncogene. 31:4848–4858. 2012. View Article : Google Scholar : PubMed/NCBI
40	Kurman RJ, Visvanathan K, Roden R, Wu TC and Shih IeM: Early detection and treatment of ovarian cancer: Shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 198:351–356. 2008. View Article : Google Scholar : PubMed/NCBI
41	Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E and Boyd J: Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 90:378–381. 2003. View Article : Google Scholar : PubMed/NCBI